Evidence map›Paper›PMID 42004602›Full record

ArticleFrontiers in pharmacology2026

Recurrent and persistent refractive errors after restarting isotretinoin treatment: a case report.

Ming-Xing Gong, Shan-Shan Li, He Huang, Fen Zhou

Abstract readCase Reports
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ming-Xing GongDepartment of Pharmacy, Chongqing Red Cross Hospital, Chongqing, China.
Shan-Shan LiDepartment of Clinical Laboratory, Chongqing Sanbo Changan Hospital, Chongqing, China.
He HuangDepartment of Dermatology, Chongqing Red Cross Hospital, Chongqing, China.
Fen ZhouDepartment of Dermatology, Chongqing Red Cross Hospital, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Isotretinoin is a vitamin A derivative widely used for moderate-to-severe acne, and is known to cause multiple systemic and ocular adverse events. Refractive errors, such as myopia and astigmatism, are commonly considered reversible after discontinuation of isotretinoin treatment. However, the visual changes and subsequent prognosis after re-exposure to isotretinoin are rarely reported. Case Presentation: A 21-year-old male initiated oral isotretinoin at 10 mg twice daily for acne vulgaris. Twelve days later, the patient developed acute visual deterioration. The eye examination revealed mild myopic astigmatism in the right eye and mild myopia in the left eye. The patient's visual acuity returned to normal at approximately 20 days after isotretinoin cessation. Then, the patient later self-restarted isotretinoin (10 mg, twice daily) for 10 days, which again resulted in decreased visual acuity. Although the patient discontinued isotretinoin, the visual acuity did not recover to baseline over a 14-month follow-up period. The Naranjo Adverse Drug Reaction Probability Scale was eight points, indicating a "probable" causal relationship between isotretinoin and refractive error. Conclusion: Myopia and astigmatism might happen concurrently after isotretinoin administration. In addition, recurrent and persistent refractive errors might occur upon restarting isotretinoin in patients with prior history of isotretinoin-related ocular complications. Clinicians should consult patients to take extra precautions on isotretinoin medication when they have a history of ocular disease or ocular complications with isotretinoin administration.

Indexed as

acne vulgarisastigmatismdisease recurrencyisotretinoinmyopiarefractive error

Identifiers

PMID42004602
PMCPMC13083116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.